Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Outcome evaluations in gout.

H Ralph Schumacher1, William Taylor, Nancy Joseph-Ridge

  • 1Division of Rheumatology, University of Pennsylvania School of Medicine, and Veterans Affairs Medical Center, Philadelphia, Pennsylvania 19104, USA. schumacr@mail.med.upenn.edu

The Journal of Rheumatology
|June 7, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of a single‑item patient‑reported measure of treatment side‑effect burden in clinical trials of rheumatic and musculoskeletal diseases using stakeholder input and large language model refinement.

Seminars in arthritis and rheumatism·2026
Same author

Measuring disease activity in juvenile systemic sclerosis: a multidisciplinary consensus from the Hamburg 2024 symposium.

Expert review of clinical immunology·2026
Same author

Integrated transcriptomic and epigenomic profiling reveals conserved molecular subtypes across systemic autoimmune diseases.

Annals of the rheumatic diseases·2026
Same author

Integrated single-cell transcriptomic analysis identifies <i>PF4</i> <sup><i>+</i></sup> <i>/PPBP</i> <sup><i>+</i></sup> megakaryocyte-like granulocytes associated with immune dysregulation in autoimmune diseases.

Biochemistry and biophysics reports·2026
Same author

Serum KL-6 and lung ultrasound B-lines: a combined non-invasive model for screening and predicting interstitial lung disease in idiopathic inflammatory myopathy.

RMD open·2026
Same author

Validity and utility of a single-item patient-reported measure of treatment-related bother in rheumatoid arthritis: A cross-sectional OMERACT study.

Seminars in arthritis and rheumatism·2026
Same journal

Clinical Features and Outcome Measures Across Still Disease (Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still Disease) Cohorts Worldwide: A Systematic Literature Review.

The Journal of rheumatology·2026
Same journal

Concurrent Calcium Pyrophosphate Deposition Disease and Gout of the Cervical Spine Presenting With Subacute Neck Pain and Radiculopathy.

The Journal of rheumatology·2026
Same journal

The Need for Weight Communication Guidelines in Pediatric Rheumatology.

The Journal of rheumatology·2026
Same journal

Bimekizumab Improves Health Status and Work Productivity, With Reduced Productivity Costs, to 3 Years in Axial Spondyloarthritis and Psoriatic Arthritis.

The Journal of rheumatology·2026
Same journal

Qualitative Analysis of Physical Activity Engagement in Women with Self-Reported SLE: The Role of Symptoms, Healthcare Providers, and the Environment.

The Journal of rheumatology·2026
Same journal

Tumoral Calcinosis-like Calcification of the Proximal Interphalangeal Joint Mimicking Rheumatoid Arthritis Flare.

The Journal of rheumatology·2026
See all related articles

Developing consensus on outcome measures for gout is crucial. Research is advancing definitions and validation for acute flares and chronic gout features, including pain and tophi.

Area of Science:

  • Rheumatology and clinical trial methodology.
  • Focuses on developing and validating outcome measures for gout management.

Background:

  • Current methods for measuring outcomes in gout lack consensus and validation.
  • Need for standardized outcome measures to accurately assess treatment efficacy and disease progression in gout.

Framework:

  • A Special Interest Group convened to identify key domains for gout outcome assessment.
  • Utilized Delphi methodology to prioritize gout flares as a primary outcome of interest.
  • Established working groups to identify and evaluate specific outcome measures for acute and chronic gout.

Implementation:

  • Initiated validation processes for various outcome measures following the OMERACT 8 meeting.
  • Progress made in defining gout flares and validating chronic gout outcome measures like tophus size and patient perceptions.

Related Experiment Videos

  • Health-related quality of life measures are being incorporated into ongoing clinical trials.

    • Implications:

    • Pain assessment using a Likert scale shows promise as a valid outcome for acute gout.
    • While final validation is pending, a clear agenda for gout outcome measure development has been established.
    • Addresses the unique challenges in evaluating gout, paving the way for standardized clinical trial endpoints.